Navigation Links
WomenHeart Urges Women to Talk With Doctors About New Study Showing Statins Prevent Heart Attacks, Deaths
Date:11/10/2008

WASHINGTON, Nov. 10 /PRNewswire-USNewswire/ -- WomenHeart today urged women to talk with their doctors about heart disease risk factors in light of new research demonstrating the impact of statin therapy (cholesterol-lowering drugs) on cardiovascular events in women. The study, called JUPITER, found that statin therapy prevents heart attacks, strokes and deaths in women - even those with normal cholesterol levels and no signs of heart disease.

"These new findings underscore the importance that women know their risk factors and ask their doctors what can be done to reduce them," said Lisa M. Tate, chief executive officer of WomenHeart: The National Coalition for Women with Heart Disease. "Heart disease is the number one killer of women, and about 500,000 die from it every year."

WomenHeart Champions are women living with heart disease who are willing to talk with media about their experience. Call 202-728-7199 or 301-213-6231

Presented at the American Heart Association's annual scientific meeting, the study found substantial reductions in deaths, strokes and heart attacks among patients taking statins. The study of nearly 18,000 patients - 38 percent of whom were women - may be the first study to demonstrate that statins prevent first heart attacks in women.

The study found that rosuvastatin (a potent statin) prevented heart attacks, strokes or death in people who had normal levels of LDL - or bad cholesterol, but high levels of a marker called C-reactive protein (CRP). This protein measures inflammation in the arteries, a condition that could lead to a heart attack. Both LDL cholesterol and CRP were significantly reduced with treatment.

While these findings could help save thousands of lives, Tate urges women to proceed with caution when considering making any changes to their heart health regimen and to be as informed as possible about their choices.

WomenHeart's Scientific Advisory Council wants women to know...

-- Statins are in a powerful class of drugs shown to reduce a person's

risk for heart disease and stroke.

-- Women known to be at risk may already be taking this medication as part

of their heart health regimen.

-- Like any drug, there are pros and cons to taking anything long term. It

is vitally important that women, who are not currently on a statin

regimen, talk with their doctor about what is right for them.

-- Discuss with your doctor whether you should have your C-reactive protein

(CRP) measured.

-- Undoubtedly, much information will be forthcoming from many sources

about the JUPITER study (http://www.crphealth.com/home/hcp/). It is

important to stay with credible sources of health and medical

information. Women should be cautious and consult their physicians

before making any changes to their heart health regimens.

WomenHeart is the only national, patient-centered organization dedicated to advancing women's heart health through advocacy, community education and patient support. A nonprofit advocacy organization, WomenHeart is a community of women heart patients and their families, health care providers, advocates and consumers committed to helping women live longer, healthier lives.

Visit WomenHeart's Web site at http://www.womenheart.org.


'/>"/>
SOURCE WomenHeart
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Medicaid Health Plans of America Urges Congress to Pass Economic Recovery Package This Session Featuring Additional Funding for Medicaid
2. Michigan Business & Professional Association Urges Legislature to Act Quickly on Individual Health Care Reform
3. Malaria No More Congratulates President-elect Obama and the New Congress and Urges Them to Uphold Their Strong Commitment to Eliminating Malaria
4. GPhA Congratulates President-Elect Barack Obama and New Congress and Urges Action on Increasing Access to Generic -- and Biogeneric -- Medicines
5. Consumers Union Urges FDA to Conduct Full Scale Safety Review of Nanoparticles in Sunscreen
6. RID Applauds Medicares New Payment Rule, Urges New York and All States to Follow
7. Child Life Council Urges Parents to Think Ahead to Ease Childs Hospital Visit
8. Testifying Before Congress, Trust for Americas Health Urges FDA Spending Cap Until Realistic Budget Request is Made
9. Red Cross Urges Safety in Wake of Hurricane Ike
10. American Red Cross Urges, Prepare for Ike
11. Consumer Reports Urges Chronic Headache Sufferers to Examine Their Use of Pain Relief Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... , ... MelaKids, a Laredo-based company, has introduced a new concept for children’s ... gives us a full supply of melanin – in the back of the eye ... pigment; however, around the age of thirty, we develop a yellow-brown pigment in the ...
(Date:9/19/2017)... , ... September 19, 2017 , ... The Workgroup ... of health IT to create efficiencies in healthcare information exchange and a trusted advisor ... of their latest industry white paper, entitled Barriers to Adoption of the ERA ...
(Date:9/19/2017)... ... ... Public outrage over the toxins that exist in tap water and the lack ... itself to research, develop and ultimately supply consumers with healthy drinking water alternatives. Vitev ... alkaline water technologies, water filtration systems, and consumer education. , ...
(Date:9/19/2017)... ... September 19, 2017 , ... Bone Solutions Inc. (BSI), an ... orthopedic medical device, OsteoCrete®. OsteoCrete® bone void filler is designed to assist with ... magnesium, a critical property for bone health and development. , “We’re excited to ...
(Date:9/19/2017)... ... September 19, 2017 , ... Ron Norman, CEO of Team Decades, ... of making a distinct rather than generic impression in the job market if one ... a stack of resumes knows that the first impression they give off is not ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... Sept. 6, 2017   PDI , a leader in ... host an educational session focused on the role of ... prevention at the 2017 Annual Scientific Meeting of the ... place at the Phoenix Convention ... Sept. 16-19, will also feature PDI,s Prevantics® Device ...
(Date:9/6/2017)... 2017 Eli Lilly and Company (NYSE: ... data for galcanezumab and lasmiditan, two investigational treatments for ... Society (IHC) taking place Sept. 7-10 in ... new, long-term data from an open-label study evaluating the ... mg and 240 mg) for the prevention of migraine. ...
(Date:9/5/2017)... NEWTOWN, Pa. , Sept. 5, 2017  Xyntek Inc. has announced another ... opened a new Midwest office to meet the growing demands of customer engagements ... Xyntek's new Midwest office is located at ... ... demands of customer engagements regionally. ...
Breaking Medicine Technology: